|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Patient Burdens and Openness to In-Home Intravesical Therapy for Bladder Cancer
|
Amanda Myers, MD, and Timothy Lyon, MD
Sam Chang hosts Amanda Myers and Tim Lyon to discuss the burdens of intravesical therapy for bladder cancer. Dr. Myers shares insights from their study on the patient-reported treatment burdens, revealing significant challenges related to travel, cost, and daily life disruptions due to the current clinic-based treatment setup.
|
|
|
|
|
|
|
|
|
|
|
|
Patient-Driven Outcomes in the CISTO Trial for High-Grade Non-Muscle Invasive Bladder Cancer
|
Angela Smith, MD, MS, & John Gore, MD, MS, FAC
Sam Chang introduces a dialogue with John Gore and Angie Smith, who are leading a trial named CISTO, aimed at addressing treatment decisions in non-muscle invasive bladder cancer.
|
|
|
|
|
|
|
|
|
|
|
|
The Economic Impact of Cystectomy vs Trimodal Bladder Therapy
|
|
Stephen B. Williams, MD, MS, FACS
|
| Zachary Klaassen and Stephen Williams delve into the economic and treatment implications of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer.
|
|
|
|
|
|
|
|
|
|
|
|
| Small Cell Neuroendocrine Carcinoma of Urinary Tract: Relapse Factors & Treatment |
| Omar Alhalabi, MD |
| Ashish Kamat interviews Omar Alhalabi about research on small cell neuroendocrine carcinoma of the urinary tract. Dr. Alhalabi discusses the study's findings on prognostic factors for relapse in surgically resected cases. |
|
|
|
|
|
|
|
|
|
|
|
| The Best of ASCO 2024 in Advanced Bladder Cancer |
| Shilpa Gupta, MD |
| Ashish Kamat interviews Shilpa Gupta about the best of ASCO 2024 in advanced bladder cancer. Dr. Gupta discusses three abstracts: the CheckMate-901 trial's analysis of complete responders to Nivolumab plus gemcitabine-cisplatin in lymph node-only metastatic urothelial cancer; patient-reported outcomes from the EV-302 trial comparing enfortumab vedotin plus pembrolizumab to platinum chemotherapy; and circulating tumor DNA assessment in the KEYNOTE-361 trial. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
WRITTEN CONFERENCE COVERAGE SUMMARIES BY CLINICIANS FOR CLINICIANS |
|
|
|
|
| Tailoring Treatment and Navigating Patient Preferences
|
| Samuel U. Takvorian, MD, MS
|
| A the 2024 ASCO annual meeting Dr. Samuel Takvorian discussed the following three abstracts: “Effects of immune-enhancing nutrition on radical cystectomy outcomes: Primary results from the randomized phase III double-blind clinical trial (S1600)”, “Patient-reported outcomes from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab versus platinum-based chemotherapy in previously untreated locally advanced or metastatic urothelial cancer”, and “Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer”.
|
|
|
|
|
|
| Bladder Cancer Care Implementation: NCCN Bladder Cancer Guidelines
|
| Thomas Flaig, MD
|
| The 2024 BCAN Think Tank was host to an implementation science session that addressed bridging evidence generation to practice in bladder cancer care. Dr. Thomas Flaig provided an overview of the NCCN and discussed bladder cancer care implementation within the NCCN bladder cancer guidelines.
|
|
|
|
|
|
|
|
|
|
|
| S1600: Effects of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes: Primary Results from the Randomized Phase III Double-Blind Clinical Trial
|
| Jill Hamilton-Reeves, PhD, RD, CSO
|
| The 2024 ASCO annual meeting featured an oral abstract session on bladder cancer, and a presentation by Dr. Jill Hamilton-Reeves discussing the primary results of S1600 assessing the effects of immune-enhancing nutrition on radical cystectomy outcomes.
|
|
|
|
|
|
| Implementation of Smoking Cessation for Patients with Bladder Cancer
|
| Marc Bjurlin, DO, MSc
|
| The 2024 BCAN Think Tank was host to an implementation science session that addressed bridging evidence generation to practice in bladder cancer care. Dr. Marc Bjurlin provided an overview of smoking cessation implementation efforts for patients with bladder cancer.
|
|
|
|
|
|
| Identifying Individual and Community-Level Drivers of Disparities in Bladder Cancer Clinical Trials Participation
|
| Rishi Sekar, MD
|
| The 2024 BCAN Think Tank was host to a BCAN 2023 Patient Centered Clinical Young Investigator Awardee session. Dr. Rishi Sekar, the Patient-Centered Clinical Research Young Investigator Awardee, discussed his work evaluating individual and community-level drivers of disparities in bladder cancer clinical trials participation.
|
|
|
|
|
|
| Multidisciplinary Management of Sexual and Gender Minorities with Bladder Cancer - Beyond the Abstract
|
| Hannah Ahrendt, Helen Sun MD, & Laura Bukavina MD MPH MSc
|
| In this physician abstract commentary written by Ahrendt H. et al. key considerations for the evaluation, diagnosis, and treatment of sexual and gender minority individuals with bladder cancer are highlighted.
|
|
|
|
|
|
| A Podcast on Practical Considerations in Patients with Advanced Urothelial Cancer Receiving First-Line Cisplatin- or Carboplatin-Based Chemotherapy Followed by Avelumab Maintenance in a Changing Therapeutic Landscape - Beyond the Abstract |
| Jun Gong, MD |
| Jun Gong discusses practical considerations for treating metastatic urothelial carcinoma (UC) patients with first-line platinum-based chemotherapy followed by avelumab maintenance, as established by the JAVELIN Bladder 100 trial. This article highlights the evolving treatment landscape with new FDA-approved regimens, though availability and financial considerations may limit the global adoption of these newer therapies. |
|
|
|
|
|
| Characterization of Complete Responders to Nivolumab + Gemcitabine-Cisplatin vs Gemcitabine-Cisplatin Alone and Patients with Lymph Node–only Metastatic Urothelial Carcinoma from the CheckMate 901 Trial
|
| Matt Galsky, MD, FASCO
|
| Matt Galsky presents a post hoc analysis from the CheckMate 901 trial, comparing complete responders to nivolumab plus gemcitabine-cisplatin versus GC alone in patients with lymph node-only metastatic urothelial carcinoma. The analysis revealed that over half of the complete responders had lymph node-only mUC, with those receiving nivolumab + GC demonstrating significantly improved overall survival and progression-free survival compared to GC alone.
|
|
|
|
|
|
| Avelumab First Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Histological Subtypes
|
| Yohann Loriot, MD, Ph.D.
|
| Yohann Loriot presents long-term outcomes from the JAVELIN Bladder 100 trial, focusing on patients with advanced urothelial carcinoma and histological subtypes. The analysis showed that avelumab first-line maintenance therapy significantly prolonged overall survival and progression-free survival compared to best supportive care alone in patients with histological subtypes, consistent with outcomes in the overall trial population.
|
|
|
|
|
|
|
|
